Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (June 2022)

41 slides from Windtree Therapeutics's investor presentation, Jun 6, 2022

  1. Slide 1: Windtree Therapeutics Company Overview

    Windtree Therapeutics Company Overview June 5, 2022 WINDTREE (NASDAQ: WINT) THERAPEUTICS

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Si @ This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Co

  3. Slide 3: Windtree Therapeutics Highlights

    Windtree Therapeutics Highlights GF Biopharmaceutical company with advanced clinical programs spanning 4 @ cardiovascular and respiratory disease states (NASDAQ: WINT) SG Clinical programs focused on significant markets with high unmet needs and with supportive regulatory paths: * One clinical progr

  4. Slide 4: Windtree Therapeutics Pipeline

    Windtree Therapeutics Pipeline eases jue FDA Fast Track —_|staroxime Phase 2b Study start up ongoing for second Phase 2b Designation (Acute Heart Failure) clinical trial in ~300 patients targeted to start once clinical trial operations are fully funded Potential for Istaroxime Phase 2 = Positive Pha

  5. Slide 5: Strategy for Value Creation

    Strategy for Value Creation Q2 Q3 Q4 Qi Q2 Q3 Q4 ai Q2 Q3 Istaroxime Cardiogenic Shock Mectw/FDA;EMA Ii Phase 2 SEISMIC Extension Study @ —fonror2 (seismic) - — Positive SCAI Stage C Study Results ns Istaroxime Acute Heart Failure Study “18 months to execute; EOP2 Mtg. A Heart Failure {transition to

  6. Slide 6: Istaroxime

    Istaroxime Dual Mechanism SERCA2a Activator Acute Heart Failure and : Early Cardiogenic Shock Se winotReEe we ee

  7. Slide 7: Heart Failure — Large, Growing Market But Underserved

    Heart Failure — Large, Growing Market But Underserved The prevalence and mortality of heart failure is high and increasing > 6MUSS., 20M+ worldwide patients » #1 cause of U.S. hospitalization in patients > 65 years old; > 1.3M admissions annually (U.S.) ~1.5M admissions annually (E.U.) > In-patient

  8. Slide 8: Acute Heart Failure — Significant Unmet Clinical Need

    Acute Heart Failure — Significant Unmet Clinical Need : itty * Clinical objectives for AHF = Current approaches to acutely improve patient management include: cardiac function are associated with * Relieve pulmonary congestion unwanted effects: and general edema (e.g., “dry ¢ Heart rhythm disturbanc

  9. Slide 9: Istaroxime — Novel First-in-Class Dual Mechanism

    Istaroxime — Novel First-i Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart Dual Mechanism "pee = Inhibition of the sodium- Stimulation of SERGAZS actviEy. enhances calcium reuptake resulting in potassium pump and effectson IStarOXiIMe improvemen

  10. Slide 10: Istaroxime AHF Phase 2a & 2b Studies — Summary

    Istaroxime AHF Phase 2a & 2b Studies — Summary Multicenter, double blind, placebo-controlled, parallel group in 240 patients co n=120 ADHF Patients Dosing= Piase 0.5, 1, 1.5 us/ke/min Dosing= 0.5, 1.0 pg/ke/min Phase n=120 2b ADHF Patients (dyspnee plus need for IV furosemide 2 40mg) 5 6 hour Infusi

  11. Slide 11: Primary Endpoint Achieved

    Primary Endpoint Achieved Significant Changes in E/e' Ratio and Stroke Volume Istaroxime 0.5 pg/kg/min vs. placebo Istaroxime 1.0 pg/kg/min vs. placebo 20 20 10 1 T 00 ao 4 8 8 320 g. B20 ys 4 Fe’ 3 so | 50 Infusion period Infusion period is so Ai csiealiei Pa e * p-value = 0.029 pevalee secre 20 70

  12. Slide 12: Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve

    Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve Istaroxime 0.5 ug/kg/min vs. placebo Istaroxime 1.0 ug/kg/min vs. placebo n er ° 3 ? . — Systolic & Blood 3 Pressure i (sBP) tnfusion period * infusion period | s 7 * p-value = 0.011, ** p-values < 0.006, ett a e

  13. Slide 13: Heart Rate Decreased and No Increases in Cardiac Troponins

    Heart Rate Decreased and No Increases in Cardiac Troponins Istaroxime 0.5 pg/kg/min vs. placebo Infusion period Lg * p-value = 0.014 re Change in Heart Rate (bpm) SabouD = Placebo Cohort 1 —@eeistaroxime 0. pe/ka/min cTnT — 0 to 24 hours Istaroxime 1.0 pg/kg/min vs. placebo Infusion period * pvalup=

  14. Slide 14: Favorable Profile Observed with 24-hour Holter Monitoring

    Favorable Profile Observed with 24-hour Holter Monitoring Clinically Significant Arrhythmias Clinically Significant Arrhythmias 220% —ros% 205% 105% 250% 200% 200% 100% 200% 80% 15.0% 2.9% 60% ox 0.0% : 100% 40% 24% 24% 24% | | im a - 00% 00% Baseline Day (Infusion) Day Baseline Day (Infusion) Day 2

  15. Slide 15: Istaroxime — Acute Heart Failure Next Steps

    Istaroxime — Acute Heart Failure Next Steps Objective: Optimize therapy and employ study enrichment strategies to create strong Phase 3 and partnership position Execute an additional study designed to complete Phase 2 and inform Phase 3 - 300 patients, 60 centers globally* Enrich therapeutic impact

  16. Slide 16: Istaroxime Early Cardiogenic Shock

    Istaroxime Early Cardiogenic Shock Additional potential indication in active clinical development

  17. Slide 17: Cardiogenic Shock

    Cardiogenic Shock Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output > Caused by severe impairment of cardiac function that results in diminished cardiac output, end-organ hypoperf

  18. Slide 18: Early Cardiogenic Shock Treatment

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity to Address Significant Unmet Need » No satisfactory pharmacological intervention to reverse the conditions * Available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, renal dysfunction an

  19. Slide 19: Early Cardiogenic Shock Treatment: Accelerated Pathway

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Pathway FDA Regulatory Commentary with Break-Through Therapy Designation Potential Sponsors are potentially not required to show benefit other than an increase in blood pressure to support approval of drugs to treat h

  20. Slide 20: SEISMIC Early Cardiogenic Shock Study

    SEISMIC Early Cardiogenic Shock Study Early cardiogenic shock study: Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure 60 patients in early cardiogenic shock (SBP 75-90mmHg) with AHF Study drug was infused for 24 hours in a 1:1 randomization

  21. Slide 21: Primary Endpoint — Difference in SBP Profile

    Primary Endpoint — Difference in SBP Profile

  22. Slide 22: Secondary Results - Systolic BP Improvements Persisted over 24 Hours

    Secondary Results - Systolic BP Improvements Persisted over 24 Hours Systolic Blood Pressure mITT Population LA pert 0 2 24 Hours from Infusion Inititation Change in SBP (mmHg) (p=0.025 for AUC) —®-Istaroxime --*- Placebo Se winotReEe ue es

  23. Slide 23: Cardiac Function Improvement

    Cardiac Function Improvem Echocardiography demonstrated improvements in key systolic and diastolic cardiac function measures including: © Cardiac index significantly increased ¢ Stroke volume index substantially increased approaching statistical significance * Other echocardiographic measurements im

  24. Slide 24: Treatment was Associated with a Positive Renal Profile

    Treatment was Associated with a Positive Renal Profile * Renal function was not decreased in istaroxime treated patients Estimated Glomerular Filtration Rate mITT Population ‘ 5: i RSL é Sac. | Ze — i [-*f==s a =~ -4 4 al = & ~-L- j L , SRE Te ee Oe SR SO Hours from Infusion initiation —O btaroxime

  25. Slide 25: Comparison of Doses

    Comparison of Doses 1.0 ug/kg/min Produced a Favorable Effect on SBP 1.0 ug/kg/min dosing was associated with: * Early, rapid SBP increase and improvement in more echocardiographic parameters of cardiac function * More favorable adverse event, serious adverse event and clinical event profile 16 Chan

  26. Slide 26: SEISMIC Results Summary

    » SEISMIC Results Summary SEISMIC was a positive study in early cardiogenic shock patients Systolic blood pressure significantly increased within the first 6 hours of initiating the infusion (p=0.017) and the increase was maintained throughout the 24-hour infusion (p=0.025) ©. SBP increases were rap

  27. Slide 27: SEISMIC Trial — Relevance to the Acute Heart Failure Program

    SEISMIC Trial — Relevance to the Acute Heart Failure (AHF) Program = The early cardiogenic shock trial results are consistent with Windtree’s Phase 2 AHF studies and complementary to further advancement in AHF. = While SEISMIC was an early cardiogenic shock study, the patients studied had very sever

  28. Slide 28: Cardiogenic Shock Development Strategy

    Cardiogenic Shock Development Strategy SEISMIC Extension Study —~ * Optimize the dosing = Additional characterization of effect SEISMIC Study Phase 3* * Proof of Concept 7 = Execute EOP2 meeting " SCAI Stage B due to AHF with these 3 studies = Learnings about dosing augmented by AHF and effect, etc.

  29. Slide 29: SEISMIC Extension Study

    SEISMIC Extension Study (amendment to the ECS study) Following the positive results in the early cardiogenic shock study, an extension Study is planned to support ongoing development in early cardiogenic shock and acute heart failure Study objectives: v Advance the characterization of the physiology

  30. Slide 30: Planned SCAI Stage C Cardiogenic Shock Patient Study

    Planned SCAI Stage C Cardiogenic Shock Patient Study While a smaller group than SCAI stage B, given positive results in early cardiogenic shock, the strategy is to gain experience in more severe, SCAI stage C patients to support both regulatory, development and commercial strategies Study objectives

  31. Slide 31: Next Generation, Oral SERCA2a Activators

    Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCA2a Dual Mechanism, (SERCA2a Activators & Na+/K+) Compounds * Oral &i.v. therapies for chronic heart = “Next generation istaroxi

  32. Slide 32: Summary - Potential to Create Value

    Summary - Potential to Create Value Istaroxime has been successfully studied in 7 clinical trials (3 being Phase 2 trials) with approximately 300 patients treated with istaroxime to date (and plans to grow) Istaroxime has positive Phase 2a and 2b results demonstrating: v Improved cardiac function —

  33. Slide 33: Financial Summary & Capitalization as of March 31, 2022

    Financial Summary & Capitalization as of March 31, 2022 = Cash & Equivalents of ~$15.5 million Securities Common Stock 29,406,172 Options (WAEP $7.81) 4,163,934 Restricted Stock Units 554,000 Warrants (WAEP $9.43) 16,628,802 Fully Diluted Equivalents 50,752,908 Se winotReEe we ies 33

  34. Slide 34: Strategy for Value Generation

    Strategy for Value Generation Ee we WINDTREE THERAPEUTICS Communicate Our Milestones: Share the results from our late-stage clinical programs for achievement of milestones and news flow that may be growth catalysts - set new milestones for the future G Transactions: * Secure focused BD transactions

  35. Slide 35: Windtree Therapeutics

    Windtree Therapeutics “Striving to Deliver Hope for a Lifetime!” Se winotReEe ue

  36. Slide 36: Appendix

    Appendix

  37. Slide 37: Acute Heart Failure

    Acute Heart Failure Significant Healthcare Issue with Significant Unmet Clinical Need = Patients with low blood pressure (SBP) and peripheral hypoperfusion are high risk, challenging patients. These patients are also generally resistant to diuretic therapy and often discharged in a sub-optimal state

  38. Slide 38: Istaroxime Phase 2a (HORIZON-HF) Study

    Istaroxime Phase 2a (HORIZON-HF) Study Primary Endpoint: PCWP Significant Improvements = Multicenter, double blind, placebo- 1 sas oe controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU Hospitalized with AHF, with criteria including: © LVEF < 35% © SBP 90-150

  39. Slide 39: Istaroxime AHF Phase 2b Adverse Events

    Istaroxime AHF Phase 2b Adverse Events Istaroxime 0.5 Istaroxime 1.0 Ue ahet mg/Kg/min mg/Kg/min (n=41) () All adverse events 23 (59.0%) 31(75.6%) 33 (82.5%) ‘Adverse events leading to — 1 (2.6%) . 4 (10.0%) Serious adverse events 2 (5.1%) 2 (4.9%) 6 (15.0%) Cardiac death : 2 1 (2.59) Cardiogenic sh

  40. Slide 40: SEISMIC: Serious Adverse Events and Adverse Drug Reactions

    SEISMIC: Serious Adverse Events and Adverse Drug Reactions Event Istaroxime ( ) All adverse events 27 (93%) 25 (81%) Serious adverse events 6 (21%) 6 (19%) Cardiac arrest 1 (3%) 0) Cardiac failure 2(7%) 2 (6%) Cardiac failure acute 0 13%) Cardiac ventricular thrombosis 0 18%) Cardiac artery stenosis

  41. Slide 41: SEISMIC: Safety and Efficacy Appeared more Favorable with 1.0 vs 1.5 ug/kg/min

    SEISMIC: Safety and Efficacy Appeared more Favorable with the 1.0 vs 1.5 yg/kg/min and Placebo 1.0 ug/kg/min dosing was associated with: ¢ Early SBP increase and improvement in more echocardiographic parameters of cardiac function * More favorable adverse event, serious adverse event and clinical ev

Windtree Therapeutics — Investor Presentation (June 2022) on 6ix